Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Lrg1 Is An Adipokine That Mediates Obesity-Induced Hepatosteatosis And Insulin Resistance, Sijia He, Jiyoon Ryu, Juanhong Liu, Hairong Luo, Ying Lv, Paul R. Langlais, Jie Wen, Feng Dong, Zhe Sun, Ravindranath Duggirala
Lrg1 Is An Adipokine That Mediates Obesity-Induced Hepatosteatosis And Insulin Resistance, Sijia He, Jiyoon Ryu, Juanhong Liu, Hairong Luo, Ying Lv, Paul R. Langlais, Jie Wen, Feng Dong, Zhe Sun, Ravindranath Duggirala
School of Medicine Publications and Presentations
Dysregulation in adipokine biosynthesis and function contributes to obesity-induced metabolic diseases. However, the identities and functions of many of the obesity-induced secretory molecules remain unknown. Here, we report the identification of leucine-rich alpha-2-glycoprotein 1 (LRG1) as an obesity-associated adipokine that exacerbates high fat diet–induced hepatosteatosis and insulin resistance. Serum levels of LRG1 were markedly elevated in obese humans and mice compared with their respective controls. LRG1 deficiency in mice greatly alleviated diet-induced hepatosteatosis, obesity, and insulin resistance. Mechanistically, LRG1 bound with high selectivity to the liver and promoted hepatosteatosis by increasing de novo lipogenesis and suppressing fatty acid β-oxidation. LRG1 …
Association Of Hiv-1 Infection And Antiretroviral Therapy With Type 2 Diabetes In The Hispanic Population Of The Rio Grande Valley, Texas, Usa, Juan Carlos Lopez Alvarenga, Dora A. Martinez, Alvaro Diaz-Badillo, Liza D. Morales, Rector Arya, Christopher Jenkinson, Joanne E. Curran, John Blangero, Ravi Duggirala, Srinivas Mummidi, Ruben D. Martinez
Association Of Hiv-1 Infection And Antiretroviral Therapy With Type 2 Diabetes In The Hispanic Population Of The Rio Grande Valley, Texas, Usa, Juan Carlos Lopez Alvarenga, Dora A. Martinez, Alvaro Diaz-Badillo, Liza D. Morales, Rector Arya, Christopher Jenkinson, Joanne E. Curran, John Blangero, Ravi Duggirala, Srinivas Mummidi, Ruben D. Martinez
School of Medicine Publications and Presentations
The Rio Grande Valley (RGV) in South Texas has one of the highest prevalence of obesity and type 2 diabetes (T2D) in the United States (US). We report for the first time the T2D prevalence in persons with HIV (PWH) in the RGV and the interrelationship between T2D, cardiometabolic risk factors, HIV-related indices, and antiretroviral therapies (ART). The PWH in this study received medical care at Valley AIDS Council (VAC) clinic sites located in Harlingen and McAllen, Texas. Henceforth, this cohort will be referred to as Valley AIDS Council Cohort (VACC). Cross-sectional analyses were conducted using retrospective data obtained from …
Sacubitril/Valsartan Inhibits Obesity-Associated Diastolic Dysfunction Through Suppression Of Ventricular-Vascular Stiffness, Annayya R. Aroor, Srinivas Mummidi, Juan C. Lopez-Alvarenga, Nitin Das, Javad Habibi, Guanghong Jia, Guido Lastra, Bysani Chandrasekar
Sacubitril/Valsartan Inhibits Obesity-Associated Diastolic Dysfunction Through Suppression Of Ventricular-Vascular Stiffness, Annayya R. Aroor, Srinivas Mummidi, Juan C. Lopez-Alvarenga, Nitin Das, Javad Habibi, Guanghong Jia, Guido Lastra, Bysani Chandrasekar
School of Medicine Publications and Presentations
Objective: Cardiac diastolic dysfunction (DD) and arterial stiffness are early manifestations of obesity-associated prediabetes, and both serve as risk factors for the development of heart failure with preserved ejection fraction (HFpEF). Since the incidence of DD and arterial stiffness are increasing worldwide due to exponential growth in obesity, an effective treatment is urgently needed to blunt their development and progression. Here we investigated whether the combination of an inhibitor of neprilysin (sacubitril), a natriuretic peptide-degrading enzyme, and an angiotensin II type 1 receptor blocker (valsartan), suppresses DD and arterial stiffness in an animal model of prediabetes more effectively than valsartan …